Published in Biotech Business Week, February 24th, 2003
This kit, using technology licensed exclusively to Molecular Devices by Bayer, AG, addresses a broad spectrum of drug targets in high-throughput screening, including those that have proved problematic with other calcium assay formats.
Cell-based calcium flux assays are considered one of the most important screening techniques used in pharmaceutical drug discovery, and all of the major pharmaceutical companies utilize Molecular Devices' FLIPR system for these assays. However, many drug...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.